ESG

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A Carroll, Ohio firm keeps winning top awards for managing wealth. We explore how its strategies are enabling affluent retirees to navigate uncertainty.

A government crackdown on clergy and a top businessman raises serious questions about Armenia's judicial independence, spooking investors and allies alike.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

A utility is slashing its carbon footprint by 99.9% not with solar or wind, but with an invisible innovation that fixes the grid from the inside out.

Beneath the glamour of superyacht dining lies a high-stress world. A unique competition is driving innovation in culinary arts and crew wellbeing.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

New clinical data on VALTOCO nasal spray shows significant benefits for young children, reinforcing the critical need for rapid seizure intervention.

KB Home's new Port Orchard community isn't just about houses; it's a new model for building that merges personalization, deep energy savings, and market strategy.

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.

Parsons Corporation has secured a key position on a $3.5 billion DTRA contract, reaffirming its critical role in global efforts to counter weapons of mass destruction.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?

In a routine filing with major implications, Albion Crown VCT directors reinvest dividends, signaling deep faith in the VCT model as tax rules evolve.

With new funding, Japan's Helical Fusion is racing to build a fusion plant by the 2030s. Can its unique stellarator technology win the clean energy race?

A new federal investment aims to tackle the hidden crisis of violence against disabled women by scaling a support model built on shared experience.